Provided by Tiger Trade Technology Pte. Ltd.

Harrow Health Inc

30.62
+0.27000.89%
Post-market: 30.870.2500+0.82%16:48 EDT
Volume:707.62K
Turnover:21.62M
Market Cap:1.15B
PE:-30.64
High:31.11
Open:30.09
Low:29.90
Close:30.35
52wk High:54.85
52wk Low:28.54
Shares:37.49M
Float Shares:28.93M
Volume Ratio:1.32
T/O Rate:2.45%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.9993
EPS(LYR):-0.1400
ROE:-116.07%
ROA:-0.45%
PB:75.52
PE(LYR):-218.71

Loading ...

Harrow, - Deal Valued at up to $100 Mln with $30 Mln Cash at Closing

THOMSON REUTERS
·
Aug 06

Earning Preview: Harrow Health Inc revenue is expected to increase by 6.59%, and institutional views are bullish

Earnings Agent
·
Aug 03

Harrow Updates Financial Calendar with Upcoming Quarterly Results Release and Investor Call

Reuters
·
Jul 27

Harrow Price Target Maintained with a $63.00/share by BTIG

Dow Jones
·
Jul 21

Samsung Bioepis and Harrow Present Interim Data from a Large-Scale Post-Marketing Surveillance Study on SB11 (BYOOVIZ® / AMELIVU®), a Biosimilar to Lucentis (ranibizumab), at ASRS 2026

GlobeNewswire
·
Jul 20

Harrow Says QUELL Trial of Iheezo Posts Topline Data in Q4 2026

Reuters
·
Jul 20

Harrow Highlights Growing Clinical Evidence Supporting IHEEZO® and BYOOVIZ® at ASRS 2026 Annual Meeting

GlobeNewswire
·
Jul 20

Harrow Among 3 Prime Growth Stocks With Significant Insider Ownership

Simply Wall St.
·
Jul 17

Craig-Hallum Sticks to Its Buy Rating for Harrow Health (HROW)

TIPRANKS
·
Jul 13

Harrow (HROW) Could Be 38% Undervalued Following BYOOVIZ Launch

Simply Wall St.
·
Jul 03

Analysts Are Bullish on These Healthcare Stocks: Plus Therapeutics (PSTV), Harrow Health (HROW)

TIPRANKS
·
Jul 01

Harrow Expands Retina Portfolio With US Launch of Byooviz

MT Newswires Live
·
Jul 01

Harrow announces commercial launch of Byooviz in the U.S.

TIPRANKS
·
Jul 01

Samsung Bioepis Relaunches Byooviz® (ranibizumab-nuna) in the United States in Partnership with Harrow

THOMSON REUTERS
·
Jul 01

Harrow Announces Commercial Launch of BYOOVIZ® in the United States

GlobeNewswire
·
Jul 01

Harrow holds annual shareholder meeting, elects four directors

Reuters
·
Jun 22

Harrow (HROW) Stock After VERKAZIA Relaunch A Fresh Look At The Valuation Gap

Simply Wall St.
·
Jun 12

What Harrow (HROW)'s VERKAZIA Re‑Launch in Pediatric VKC Means For Shareholders

Simply Wall St.
·
Jun 11

Harrow Shares Rise on Relaunch of Pediatric Eye Disease Treatment

Dow Jones
·
Jun 10

Harrow Relaunches Verkazia for Vernal Keratoconjunctivitis

MT Newswires Live
·
Jun 10